<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02867163</url>
  </required_header>
  <id_info>
    <org_study_id>TXA in TKR</org_study_id>
    <nct_id>NCT02867163</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid and Blood Clots in Knee Surgery</brief_title>
  <official_title>Does the Intraoperative Administration of Tranexamic Acid (TXA) Increase the Incidence of Deep Venous Thrombosis in Total Knee Arthroplasty?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of New Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational trial to estimate the incidence of deep vein thrombosis (DVT) in
      total knee replacement patients who received an intraoperative dose of tranexamic acid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is anticipated to consist of 30 participants over 18 years of age scheduled for
      total knee arthroplasty at Sandoval Regional Medical Center with administered intraoperative
      tranexamic acid, who do not meet the exclusion criteria. The patients will be examined on
      postoperative day 1. Lower-extremity ultrasound will be used to screen for deep vein
      thrombosis (DVT). Incidence data for DVT will then be compared with the historical incidence
      rate at our institution for total knee arthroplasty without the use of tranexamic acid, which
      is approximately 12%. Patients found on screening to have deep vein thrombosis will be
      referred for appropriate care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Deep vein thrombosis</measure>
    <time_frame>One day</time_frame>
    <description>Incidence of deep vein thrombosis diagnosed by ultrasound scan on postoperative day 1</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>Knee replacement patients receiving TXA</arm_group_label>
    <description>Patients who receive tranexamic acid during total knee replacement surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Intravenous or local administration of TXA, in any dosage</description>
    <arm_group_label>Knee replacement patients receiving TXA</arm_group_label>
    <other_name>Lysteda</other_name>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients having total knee replacement at Sandoval Regional Medical Center in Rio Rancho,
        New Mexico, and who receive an intraoperative dose of tranexamic acid to control surgical
        bleeding
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients scheduled for total knee arthroplasty at Sandoval Regional Medical
             Center with an intraoperative dose of tranexamic acid

        Exclusion Criteria:

          -  Previous deep vein thrombosis or pulmonary embolism episode

          -  Known coronary artery disease or peripheral vascular disease

          -  Previously diagnosed hypercoagulable states (e.g. Leiden factor V, antiphospholipid
             antibody, protein C or S deficiency)

          -  Pregnancy

          -  Creatinine clearance less than 30 ml/min

          -  Non-fluency in English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Siegel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tim Petersen, PhD</last_name>
    <phone>5052721762</phone>
    <email>timpetersen@salud.unm.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sandoval Regional Medical Center</name>
      <address>
        <city>Rio Rancho</city>
        <state>New Mexico</state>
        <zip>87144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Siegel, MD</last_name>
      <phone>505-272-2610</phone>
      <email>dsiegel@salud.unm.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2016</study_first_submitted>
  <study_first_submitted_qc>August 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2016</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of New Mexico</investigator_affiliation>
    <investigator_full_name>David Siegel</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

